Product Description
Mechanisms of Action: LOXL2 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Cholangitis, Sclerosing|Pancreatic Cancer|Adenocarcinoma|Liver Cirrhosis|Hepatitis C|Coinfection|Hepatitis A|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Liver Cirrhosis, Alcoholic|Idiopathic Interstitial Pneumonias|Idiopathic Pulmonary Fibrosis|Hepatitis, Alcoholic|Colorectal Cancer|Myelofibrosis|Thrombocytosis|Polycythemia Vera|Thrombocythemia, Essential
Phase 1: Oncology Solid Tumor Unspecified|Idiopathic Interstitial Pneumonias|Idiopathic Pulmonary Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2012-002489-11 | P2 |
Terminated |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Liver Cirrhosis |
2019-01-26 |
|
| 2012-002488-88 | P2 |
Completed |
Hepatitis, Alcoholic|Liver Cirrhosis|Non-alcoholic Steatohepatitis |
2016-12-29 |
|
| NASH | P2 |
Terminated |
Liver Cirrhosis|Non-alcoholic Steatohepatitis |
2016-09-26 |
|
| 2012-002473-61 | P2 |
Completed |
Cholangitis, Sclerosing |
2016-08-24 |